News from CSL Behring Canada A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 09, 2017, 08:00 ET Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Global biotherapeutics leader CSL Behring announced that results were published in The Lancet Neurology from its PATH study (Polyneuropathy And...


Oct 29, 2017, 14:30 ET Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting

Global biotherapeutics leader CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA® reduced the median...


Oct 24, 2017, 08:00 ET New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Global biotherapeutics leader CSL Behring announced today that new data will be presented for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous...


Oct 12, 2017, 09:00 ET CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same

CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association's (AHA) Hands-Only™...


Sep 28, 2017, 10:30 ET Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

Global biotherapeutics leader CSL Behring today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved AFSTYLA®...


Sep 28, 2017, 08:00 ET Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders

The Great Lakes Hemophilia Foundation (GLHF) headquartered in Milwaukee, Wis., the New York City Hemophilia Chapter (NYCHC) and the Ohio Bleeding...


Sep 14, 2017, 19:50 ET CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin...


Sep 14, 2017, 05:28 ET CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI

Global biotherapeutics leader CSL Behring today announced that its "Join Together" campaign at the 2017 European Society for Immunodeficiencies...


Aug 28, 2017, 08:39 ET CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the...


Jul 25, 2017, 08:00 ET HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema

Global biotherapeutics leader CSL Behring announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...


Jul 21, 2017, 09:54 ET CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of...


Jul 19, 2017, 09:30 ET FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's...


Jul 12, 2017, 09:00 ET New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B

CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low...


Jul 11, 2017, 06:30 ET CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society's annual meeting the winners of its annual Interlaken...


Jul 10, 2017, 09:00 ET New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A

CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in...


Jul 06, 2017, 09:00 ET New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017

CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...


Jun 23, 2017, 14:16 ET FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved...


May 19, 2017, 08:00 ET New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award

CSL Behring received the National Organization for Rare Disorders' (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...


Apr 19, 2017, 14:00 ET Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA®...


Apr 10, 2017, 11:00 ET Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 4...


Mar 31, 2017, 10:00 ET La Fondation Jeffrey Modell va déployer le premier réseau nord-africain pour le traitement de l'immunodéficience primaire

CSL Behring sponsorise le premier réseau de ce genre sur le continent africain Le leader mondial des produits biothérapeutiques CSL Behring...


Mar 31, 2017, 10:00 ET Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish...


Mar 29, 2017, 15:30 ET CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD)...


Mar 22, 2017, 17:16 ET New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the...


Mar 01, 2017, 09:25 ET Largest Ever CIDP Clinical Study Completed

Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...